Brief: Clinuvel Pharmaceuticals
The US Food and Drug Administration has agreed for Clinuvel Pharmaceuticals to proceed under its Investigational New Drug to conduct a Phase II clinical trial to evaluate afamelanotide as a first-in-class photoprotective drug in patients diagnosed with erythropoietic protoporphyria, a metabolic disorder characterised by absolute intolerance to light.
The US Food and Drug Administration has agreed for Clinuvel Pharmaceuticals to proceed under its Investigational New Drug to conduct a Phase II clinical trial to evaluate afamelanotide as a first-in-class photoprotective drug in patients diagnosed with erythropoietic protoporphyria, a metabolic disorder characterised by absolute intolerance to light.
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Introducing your Newsfeed
Follow the topics, people and companies that matter to you.
Find out moreRead More
Latest In Companies
Fetching latest articles